By Barbara Obstoj-Cardwell. Managing editor
Regulatory events featured in last week’s news, first with US
biotech major Biogen announcing that the US Food and Drug
Administration (FDA) has accepted its new drug application (NDA)
for tofersen, a potential treatment for amyotrophic latera
sclerosis (ALS), for priority review. Also, Swiss women’s health
specialist ObsEva suffered a setback, as the FDA said it is
seeking…
